37 results about "Meglumine diatrizoate" patented technology

A crystalline composition of pharmacologically acceptable non-toxic salt of diatrizoic acid and a low calorie non-sweetened drink mix provides an orally administrable gastrointestinal contrast medium which results in a sufficient and faster rate of contrast in poorly compliant patients undergoing computerized axial tomographic examinations for concentration and subsequent imaging evaluation of an appendix. The non-toxic salt of diatrizoic acid medium may consist of meglumine diatrizoate or sodium diatrizoate and the low calorie non-sweetened drink mix may be that sold with the trademark Crystal Light. Methods of use include orally administering individual doses of approximately 50 minutes prior to appendix visualization using computerized axial tomography.

The invention discloses a blood leucocyte separating medium and application thereof, a preparation method of the blood leucocyte separating medium, and a blood leucocyte separating vacuum blood collection tube with the blood leucocyte separating medium and application thereof. The blood leucocyte separating medium comprises glucan T500, hydroxyethyl starch, meglumine diatrizoate, water, sodium citrate, NaN3, poly(diallyldimethylammonium chloride) and polyvinyl pyrrolidone, the proportion of parts by weight of which is 18.5-21.5:1.5-2.5:2-3:69:3.8:0.1:0.05-0.15:2-3. The invention has the advantages that clinical blood collection and anticoagulant leucocyte seperation can be completed at a time, the sodium citrate in the blood leucocyte separating medium and calcium ions in blood are chelate and anticoagulant, the technical problem of damaging the liquid level layer of the separating medium does not exit, a supernatant liquor is sucked up without needing centrifugation after natural precipitation, a complex cell seperation technology is transformed into a simple blood collection seperation process, the processes are easily united, the repeatability of test results is good, and the quality controllability is strong.

The present invention is biodegradable nanometer medicine capsule with CT trace effect and its preparation process. The nanometer level capsule is a core-shell structure and has shell layer of biodegradable polymer material and core with distributed CT contrast agent and hydrophilic or water soluble medicine. The CT contrast agent is ionic or non-ionic iodine contrast agent, the ionic iodine contrast agent is meglumine iodipamide or meglumine diatrizoate, and the non-ionic iodine contrast agent is amnipague, utravist or iodized oil injection. The capsule has several functions, high medicine carrying amount, targeting and controllable release, capacity of in vitro monitoring and other features. The present invention provides one effective medicine carrier for raising curative effect, monitoring the in vivo medicine distribution and developing new medicine.

The invention discloses umbilical cord blood mesenchymal stem cell separation liquid and an umbilical cord blood mesenchymal stem cell separation flow. The separation liquid is prepared by mixing saccharosan of which the concentration is 9 percent and meglumine diatrizoate of which the concentration is 33.9 percent in the ratio of 26.88:10, wherein the concentration of the separation liquid is 1.073+/-0.01g/L. A two-step method for separating umbilical cord blood mesenchymal stem cells comprises the following steps of: 1, precipitating red cells by a hydroxyethyl starch; and 2, separating the mesenchymal stem cells by the separation liquid of which the concentration is1.073g/L. The mesenchymal stem cell with the highest proportion in umbilical cord blood can be obtained by the separation liquid and the separation flow, the proportions of lymphocytes and mononuclear cells are very low, and the obtained cells are good in state and high in activity. The used materials and reagents are medical products, are non-toxic, do not have heat sources, can be industrially produced and are convenient to store. The used method is an optimized flow, is high in stability and repeatability, can be also used for separating human marrow and peripheral blood mesenchymal stem cells, is the best method for separating and extracting the mesenchymal stem cells in the current density gradient centrifugation and is better than other products and methods.

The invention relates to a digestive tract contrast agent having the effect of treating gastrointestinal ulcer and good smearing effect. The digestive tract contrast agent disclosed by the invention comprises barium sulphate dry suspension or compound meglumine diatrizoate, sea-buckthorn oil, the root of three-nerved spicebush, patrinia, scutellaria baicalensis, cassia twig, rhizoma corydalis, liquorice, curcuma aromatic, tangerine leaf, Chinese angelica, poria cocos, thunberg fritillary bulb, radix pseudostellariae, pseudo-ginseng and pearl powder. The digestive tract contrast agent provided by the invention is scientific in composition; the preparation method of the digestive tract contrast agent in various dosage forms is simple; the prepared digestive tract contrast agent is convenient to take and can be applied to patients suffering from different cases; and the digestive tract contrast agent has good contrast effect.

The invention relates to a human bone marrow cell processing kit and a cell processing method. The human bone marrow cell processing kit is characterized by consisting of the following three reagents: No.1 reagent which, as a thinner, is 0.5-20% of a sodium chloride injection or PBS (poly butylenes succinate) liquid, No.2 reagent which, as a precipitator, is 0.5-20% of hydroxyethyl starch or methylcellulose, and No.3 reagent which, as layering liquid, is prepared from ficoll and meglumine diatrizoate and is 1.0-1.2 in density. The cell processing method comprises the following steps: adding marrow containing sodium citrate anti-coagulation liquid to a high-capacity nutrient solution bottle which contains the No.1 reagent, and then adding the No.2 reagent and uniformly shaking; standing by, sucking upper cell liquid after layering and centrifuging for 1-20min, thinning the cell liquid by virtue of normal saline after the cell liquid is centrifuged and concentrated and paving the normal saline on the upper layer of No.3 liquid, then centrifuging so that a stem cell layer is separated, collecting the stem cell layer, and cleaning cells by virtue of normal saline for later use. The cell processing method is strong in operability, high in clinical safety and convenient for clinical popularization; and the kit is easy for storage and transportation, applicable to industrial production, and convenient and rapid to use.

The invention discloses a method for separating lymphocytes and belongs to the technical field of biology. The method comprises the following steps: fully dissolving the following components that meet the medical standards: 3 to 5 parts by weight of dextran, 2 to 4 parts by weight of mycose, 0.3 to 0.8 part by weight of sodium alginate with an ultralow viscosity, 1 to 3 parts by weight of meglumine diatrizoate, and 0.1 to 0.15 part by weight of poly(diallyl dimethyl ammonium chloride) into sterile water to prepare 100 parts by weight of physiological solution; filtering the physiological solution by a filter membrane to remove the bacteria to obtain a separated liquid; adding the separated liquid into a centrifuge tube, wherein the volume of the separated liquid is not more than 1/2 of the volume of the centrifuge tube; paving a sample, which has been processed by an anticoagulant and diluted by a balanced salt solution or serum-free culture medium, on the separated liquid, carrying out centrifugation for 10 to 30 minutes at a temperature of 8 to 25 DEG C under a gravity of 200 to 800 g; wherein the sample is derived from peripheral blood, umbilical cord blood or marrow. The obtained lymphocytes have a good tumor killing activity.

The invention provides a method for separating, purifying and culturing human blood and marrow dendritic cells, which includes the following steps that: hydroxyethyl starch and meglumine diatrizoate are used for preparing human blood and marrow dendritic cell-separating solution; sodium carbonate, sodium bicarbonate and CD123 antibody are used for producing a human blood and marrow dendritic cell culture flask; L-proline, insulin, vitamin C, L-glutamine, human umbilical cord blood plasm, recombinant human fibroblast growth factor and DMEM/F12 basic medium are used for preparing human blood and marrow dendritic cell culture solution; and human blood and marrow dendritic cells are separated, purified and cultured. The method for separating, purifying and culturing human blood and marrow dendritic cells can effectively prepare a large quantity of human blood and marrow dendritic cells, and is divided into four parts, and compared with the conventional method, the method has the advantages of simple and clear operation process and shorter operation time.

The invention discloses a gastrointestinal color ultrasound contrast agent comprising Chinese herbal medicinal ingredients. The contrast agent is composed of the following components in parts by weight: 85-90 parts of barium sulfate for suspension or a compound meglumine diatrizoate contrast agent, and 10-15 parts of Chinese herbal medicinal ingredients, wherein the Chinese herbal medicinal ingredients are prepared from the following raw material medicines in parts by weight: 25-35 parts of water chestnut, 5-12 parts of fingered citron, 15-25 parts of flowers of hyacinth dolichos, 25-35 parts of herba portulacae, 25-35 parts of radix codonopsis, 25-35 parts of cortex eucommiae, 15-25 parts of fortune loosestrife herb with root, 15-25 parts of barbed shullcap herb, 15-25 parts of cortex hibisci, and 5-8 parts of corn stigma. The gastrointestinal color ultrasound contrast agent comprising the Chinese herbal medicinal ingredients can play the efficacy of dissipating heat and removing depression, tonifying middle-Jiao and Qi, nourishing the spleen and eliminating dampness, diminishing inflammation and relieving internal heat or fever, etc., has effects of improving microcirculation of gastrointestinal mucosa and promoting absorption of gastrointestinal fluid, etc., can play the nourishing and health-care effect on the stomach and intestine, is conducive to the health of the stomach and intestine, and can effectively prevent and treat gastrointestinal diseases.

The invention relates to a method using an image enhancer and the cone-beam CT (CBCT) imaging technology to detect a cracked-tooth crack. The method is characterized in that the enhancing contrast medium meglumine diatrizoate to enhance the crack, and cone-beam CT imaging development is performed rapidly after the contrast medium seeps into the crack so as to judge the position and depth of the cracked-tooth crack and distinguish the crack from a linear low-density artifact formed by root-canal filler. By the method, the accuracy, sensitivity and specificity of tooth cracking diagnosis using the CBCT can be improved effectively, and the cracked-tooth crack positioning accuracy of the CBCT can be increased.

The invention provides a separation method for separating peripheral blood mononuclear cells, and particularly relates to the field of biological medicines. The separation method comprises the following steps: S1, preparation of a separation tube: firstly, adding 2-6 ml of Percoll or polysucrose or meglumine diatrizoate cell separation liquid with the density of 1.075-1.0796 g/ml into a centrifugal tube, sucking 0.5-1.5 ml of separation gel with the density of 1.06-1.07 g/ml, adding the separation gel into a tube opening of the centrifugal tube, and carrying out horizontal centrifuging for 1-3minutes at room temperature under the centrifugal force of 800-1200 g, so that the separation gel forms an isolation layer on the liquid surface of the Percoll or polysucrose or meglumine diatrizoatecell separation liquid, and preparation of the separation tube is finished; and S2, separation of the peripheral blood mononuclear cells: adding 2-6 ml of anticoagulant whole blood into the preparedseparation tube, and carrying out horizontal centrifuging for 8-12 minutes at room temperature under the centrifugal force of 800-1200 g; sucking and discarding the uppermost liquid to remove cell fragments and platelets, directly pouring the liquid above the isolation layer into a collection tube, carrying out centrifuging for 4-6 minutes at room temperature under the centrifugal force of 600-1000 g, and resuspending the cells by using PBS to obtain the peripheral blood mononuclear cells. According to the separation method, it can be ensured that the anticoagulant whole blood can be absolutely not mixed with a cell separation medium after being added, and other cells are not polluted when the peripheral blood mononuclear cells are harvested.

The invention discloses a kit for synchronously separating various components of umbilical cord blood. The kit comprises a diluent A, a separating medium B1, a separating medium B2, a washing solution C and a lysis solution D, the diluent A is 0.9% normal saline, the separating medium B1 and the separating medium B2 are mixed solutions formed by mixing a 9% polysucrose solution and a 34% compound meglumine diatrizoate solution according to the volume ratio of 50: 19.11 and 50: 23.28 respectively, the washing solution C is 0.9% normal saline or a PBS solution without Ca < 2 + > and Mg < 2 + >, the pH of the PBS solution is 7.4 +/-0.1, and the lysis solution D is a red blood cell lysis solution. The invention provides a technology and a kit for synchronously separating umbilical cord blood platelets, red blood cells, plasma, exosomes, neutrophils and other components, industrialization can be realized, the technical problem that other components except hematopoietic stem cells in the umbilical cord blood are not synchronously separated can be solved, and full utilization of all the components in the umbilical cord blood can be greatly promoted.

The invention discloses a composition for separating lymphocytes and a separating medium thereof, and belongs to the technical field of biology. The composition for separating single cells is prepared from the following raw materials in parts by weight: 1-4 parts of dextran, 4-6 parts of trehalose, 0.3-1.5 parts of ultralow-viscosity sodium alginate, 4-7 parts of meglumine diatrizoate, 0.003-0.006 part of L-methionine, 0.008-0.011 part of L-valine and 0.01-0.012 part of L-histidine. All raw materials in the formula are in accordance with the standard of intravenous injection grade raw materials and have small uncertainty and high safety, and the separated lymphocytes have relatively good tumor-killing activity.

The invention discloses a seminal fluid leukocyte group flow type quantitative detection reagent, a kit and a detection method. The detection reagent and the kit comprise: (1) a sample treating agent containing Na2HPO4, KH2PO4 and NaCl; (2) a sample diluent, wherein the sample diluent contains Na2HPO4, KH2PO4, NaCl and KCl; (3) a sample separating agent containing polysucrose and meglumine diatrizoate; (4) an antibody, namely an IgG type monoclonal antibody of anti-human CD45 with a fluorescence label; and (5) a sample fixing agent containing paraformaldehyde. The detection method is based on a flow cytometry principle and comprises the following steps: removing impurities and non-target cells in the seminal fluid by using a sample treating agent, specifically binding a leukocyte CD45 antibody to the surfaces of leukocytes in the seminal fluid, and finally detecting specific marker fluorescence by using a flow cytometry, thereby obtaining the number of leukocytes. The method is detected and recorded by a machine, is more objective and stable than a peroxidase method, and is easy to standardize and high in specificity; and an antibody for dyeing is stable in property, long in storage time and convenient to take and use.

The invention discloses a human bone marrow and umbilical cord blood stem cell treatment kit. The stem cell treatment kit is composed of a No.1 liquid and a No.2 liquid, the percentage (%) is weight percentage (W/W), the density unit is g/ml, the solvent of the No.1 liquid and the solvent of the No.2 liquid are water; the No.1 liquid consists of 0.1%-30% of hydroxyethyl starch or 0.1%-30% of methyl cellulose; the No.2 liquid consists of a layering liquid which is prepared from polysucrose and meglumine diatrizoate, and has a density of 1.0-1.2 g/ml. In the implementation process, the reaction time can be shortened, reagents used in the scheme are fewer, and the number of obtained stem cells is larger.

The invention relates to a compound meglumine diatrizoate injection and a use method thereof. The compound meglumine diatrizoate injection is prepared from 1 part of sodium diatrizoate, 6.6 parts of meglumine diatrizoate and the balance of sterile water, wherein the total amount of the sodium diatrizoate and the meglumine diatrizoate is 90.0-110.0 percent of a labelled amount; preferably, the compound meglumine diatrizoate injection is a colorless to faint yellow clear liquid; 60 percent injection contains 292mg/ml of iodine; 76 percent injection contains 370mg/ml of iodine; the compound meglumine diatrizoate injection further comprises sodium hydroxide for adjusting the pH value to 6.5-8.0. According to the compound megumine diatrizoate injection and the use method thereof, the compound injection is stable in property, is easy to store, can be stored in a shading way at the normal temperature, is easy and convenient to operate, and can be widely applied to various people, except people suffering from iodine allergy, hepatic and renal dysfunction, active tuberculosis, multiple myeloma and hyperthyroidism.

The invention relates to multi-component blood sample density separation liquid with excellent comprehensive performance and a preparation method thereof. The density separation liquid is prepared bythe steps: by taking glucose and meglumine diatrizoate as main ingredients, adding a small amount of NaOH and ethanol, and preparing a mixed solution. The specific composition is as follows: the content of glucose is 50-90 g/L, the content of the meglumine diatrizoate is 90-140 g/L, the ethanol content is 10-15 g/L, and the pH value of the solution is 7.3+/-0.1. With the adoption of the separationliquid, blood cells with enough quantity can be quickly settled and separated, and effects of foreign similar imported products can be achieved.